Lung Cancer section

Lung Cancer News & Features

A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review

A spectrum of cutaneous toxicities from erlotinib may be a robust clinical marker for non-small-cell lung therapy: a case report and literature review

This case study presents a woman with a stage IV lung adenocarcinoma using erlotinib monotherapy, who experienced a spectrum of cutaneous toxicities.

Active postdischarge intervention reduces ER visits and costs in major thoracic surgery

An active, postdischarge intervention after thoracic surgery resulted in numerous benefits, including shorter hospital stays and cost savings with no increase in adverse outcomes.

Lung cancer survivors at high risk for recurrence, new lung cancer

Lung cancer survivors at high risk for recurrence, new lung cancer

Many lung cancer survivors are at high risk for developing recurrence of their disease or developing another another lung cancer.

Phase I trial of lung cancer drug identifies multiple types of drug resistance

Researchers urge for new targeted inhibitors and combinations to combat tumors' constant and varied molecular adaptation.

Liquid biopsy: A new tool in the management of NSCLC

Liquid biopsy: A new tool in the management of NSCLC

This developing technology allows serial monitoring to better gauge response to treatment and prognosis for patients with non-small cell lung cancer.

Lung Cancer Videos

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs